Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERYPNYSE:IKTNYSE:PLXNYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AIKTInhibikase Therapeutics$1.65-1.2%$1.96$1.12▼$4.20$122.66M0.94244,968 shs177,400 shsPLXProtalix BioTherapeutics$1.45+2.8%$1.94$0.82▼$3.10$115.43M-0.2560,434 shs708,182 shsPRMEPrime Medicine$2.65+9.5%$1.54$1.11▼$6.75$347.93M1.551.48 million shs2.65 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%IKTInhibikase Therapeutics-1.20%-2.94%-6.78%-27.95%+17.02%PLXProtalix BioTherapeutics+2.84%+3.57%-7.05%-43.80%+17.89%PRMEPrime Medicine+9.50%+47.22%+108.66%+33.17%-47.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AIKTInhibikase Therapeutics1.5757 of 5 stars3.31.00.00.00.00.01.3PLXProtalix BioTherapeutics2.7646 of 5 stars3.54.00.00.00.60.01.9PRMEPrime Medicine3.934 of 5 stars4.41.00.00.03.45.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERYPERYTECH Pharma 0.00N/AN/AN/AIKTInhibikase Therapeutics 2.50Moderate Buy$6.50293.94% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00934.48% UpsidePRMEPrime Medicine 2.75Moderate Buy$10.08280.50% UpsideCurrent Analyst Ratings BreakdownLatest ERYP, PRME, IKT, and PLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.003/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88IKTInhibikase Therapeutics$260K471.79N/AN/A$1.78 per share0.93PLXProtalix BioTherapeutics$59.76M1.93$0.08 per share17.80$0.47 per share3.09PRMEPrime Medicine$3.85M90.47N/AN/A$1.37 per share1.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/APLXProtalix BioTherapeutics$8.31M$0.04N/A4.68N/A-21.03%-30.89%-11.74%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ALatest ERYP, PRME, IKT, and PLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERYPERYTECH PharmaN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4554.57%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERYPERYTECH Pharma0.323.653.65IKTInhibikase TherapeuticsN/A0.850.85PLXProtalix BioTherapeuticsN/A1.981.27PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERYPERYTECH Pharma1.09%IKTInhibikase Therapeutics3.81%PLXProtalix BioTherapeutics16.53%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipERYPERYTECH Pharma1.94%IKTInhibikase Therapeutics7.30%PLXProtalix BioTherapeutics6.50%PRMEPrime Medicine22.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableERYP, PRME, IKT, and PLX HeadlinesRecent News About These CompaniesPrime Medicine, Inc. (NYSE:PRME) Major Shareholder David R. Liu Purchases 21,000 SharesJune 24 at 4:53 AM | insidertrades.comInsider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Purchases 21,000 Shares of StockJune 23, 2025 | marketbeat.comHead to Head Survey: Voyager Therapeutics (NASDAQ:VYGR) vs. Prime Medicine (NYSE:PRME)June 20, 2025 | americanbankingnews.comPrime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment OpportunityJune 17, 2025 | tipranks.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $31,290.00 in StockJune 17, 2025 | insidertrades.comInsider Buying: Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires 21,000 Shares of StockJune 16, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in StockJune 12, 2025 | marketbeat.comTwo Sigma Investments LP Sells 152,374 Shares of Prime Medicine, Inc. (NYSE:PRME)June 10, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 4, 2025 | marketbeat.comMillennium Management LLC Reduces Stake in Prime Medicine, Inc. (NYSE:PRME)May 30, 2025 | marketbeat.comPrime Medicine to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comPrime Medicine's (PRME) "Neutral" Rating Reaffirmed at CitigroupMay 28, 2025 | marketbeat.comCitigroup Downgrades Prime Medicine (PRME)May 28, 2025 | msn.comCiti Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market UncertaintyMay 27, 2025 | msn.com6 Analysts Assess Prime Medicine: What You Need To KnowMay 21, 2025 | nasdaq.comCEO among 25% of staff out the door at cash-strapped PrimeMay 20, 2025 | thepharmaletter.comTPrime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staffMay 20, 2025 | fiercebiotech.comFPrime Medicine claims ‘proof of concept,’ but lays off staff in pivotMay 20, 2025 | biopharmadive.comBCRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staffMay 20, 2025 | bostonglobe.comBPrime Medicine drops after cutting CGD program amid restructuringMay 20, 2025 | msn.comPrime Medicine stock plummets amid restructuring and leadership changesMay 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERYP, PRME, IKT, and PLX Company DescriptionsERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.Inhibikase Therapeutics NYSE:IKT$1.65 -0.02 (-1.20%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.65 0.00 (0.00%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Protalix BioTherapeutics NYSE:PLX$1.45 +0.04 (+2.84%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$1.44 -0.01 (-0.62%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Prime Medicine NYSE:PRME$2.65 +0.23 (+9.50%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.67 +0.02 (+0.75%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
